$SNGX

SOLIGENIX, INC.

Soligenix is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical needs. Its Specialized BioTherapeutics segment develops HyBryte, a topical synthetic hypericin treatment for cutaneous T-cell lymphoma, and other candidates for psoriasis and inflammatory diseases, including SGX302, SGX945 and SGX942. HyBryte uses visible light to activate the drug applied to skin lesions. Its Public Health Solutions segment develops vaccine and therapeutic candidates for infectious disease and biological threats, including RiVax for ricin toxin, SGX943, filovirus vaccines and CiVax for COVID-19. The segment also uses ThermoVax, a vaccine heat-stabilization platform. Soligenix receives government grant and contract funding to support programs in this segment. Its principal executive offices are in Princeton, New Jersey.

No enriched coverage for $SNGX in the last 7 days.

No SEC Form 4 filings for $SNGX in the last 30 days.

See all $SNGX insider activity →

Soligenix, Inc. (SNGX) Q3 Net Loss Falls To $1.1M; Cash Is $9.0M

Soligenix reported no revenue for Q3 2026, with a net loss of $1.1M, or $0.05 per share, down from $2.5M a year earlier. The company had $9.0M in cash at the end of the quarter. The results follow the termination of the FLASH2 trial and reduced development activities for HyBryte.

SOLIGENIX, INC. (SNGX): Submission of Matters to a Vote of Security Holders

SOLIGENIX, INC. (SNGX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. ​ To the extent required by Item 5.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. ​ As described below in Item 5.07

SNGX sentiment & insider activity

Recent SNGX coverage spans earnings, financial news and corporate actions.

What's driving SNGX

AlphAI scores every news story that mentions SNGX with an AI model for sentiment and relevance, and aggregates insider trades from SOLIGENIX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SNGX

Score
$SNGXLowShareholder vote

SOLIGENIX, INC. (SNGX): Submission of Matters to a Vote of Security Holders

SOLIGENIX, INC. (SNGX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. ​ To the extent required by Item 5.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. ​ As described below in Item 5.07

$SNGXMedAI 8/10

Soligenix culls topical lymphoma asset after Phase III miss

Soligenix terminated the Phase III FLASH2 trial for its topical CTCL therapy HyBryte (SGX301/synthetic hypericin sodium) after interim analysis indicated it was unlikely to meet primary goals. The company will shift focus to dusquetide for Behçet’s disease and pursue commercial opportunities for its ThermoVax vaccine platform. The article also notes CTCL drug approvals and sales figures.

SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Soligenix (Nasdaq: SNGX) reported no revenue for the quarter ended June 30, 2026. Net loss was $2.0 million, or ($0.12) per share, versus $2.7 million, or ($0.82) per share, a year earlier. The company said it discontinued its HyBryte (synthetic hypericin) Phase 3 FLASH2 program after a futility recommendation. Cash was about $9.8 million as of June 30, 2026.

$SNGXMedListing notice· deficiency

SOLIGENIX, INC. (SNGX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

SOLIGENIX, INC. (SNGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Soligenix, Inc._June 10, 2026 0000812796 false DE 0000812796 2026-06-10 2026-06-10 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Ea

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data

Soligenix, Inc. (SNGX) boasts a robust late-stage pipeline, featuring assets like HyBryte for CTCL, which target rare diseases and critical public health threats. The company's efforts are supported by strong clinical data, significant market potential, government funding, and experienced leadership. This positions SNGX for ongoing development and commercialization in these key therapeutic areas.

Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

Soligenix (NASDAQ: SNGX) announced positive results from a comparability study published in Oncology and Therapy, evaluating HyBryte versus Valchlor for cutaneous T-cell lymphoma (CTCL). The study showed that 60% of HyBryte-treated patients achieved treatment success after 12 weeks, compared to 20% for Valchlor, with HyBryte demonstrating greater improvement and no treatment-related adverse events. These findings suggest HyBryte is a well-tolerated and effective potential therapy for early-stage CTCL.

Related tickers